LNTH250117C155000
- 1.25
- 0.000.00%
Lantheus Newsroom
Mizuho Securities Maintains Lantheus(LNTH.US) With Buy Rating, Announces Target Price $150
Lantheus Holdings, Inc. (LNTH): A Bull Case Theory
Lantheus Holdings Analyst Ratings
Jefferies Maintains Lantheus(LNTH.US) With Buy Rating, Cuts Target Price to $135
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
JMP Securities Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $112
Strategic Acquisition and Pipeline Growth Fuel Lantheus Holdings' Buy Rating
Why Lantheus Holdings (LNTH) Stock Is Down 4%
Express News | Lantheus Holdings Shares Are Trading Lower After the Company Announced a $350 Million Acquisition
Lantheus: Neuraceq Can Be Used to Confirm Eligibility for New Alzheimer's Therapies >LNTH
Lantheus Neuraceq Is Globally Approved, F-18 Radioactive Diagnostic Agent >LNTH
Lantheus: Deal Establishes Commercial Alzheimer's Disease Franchise With Addition of Neuraceq(R) >LNTH
Lantheus: Acquisition to Immediately Co's Enhance Growth Profile >LNTH
Express News | Life Healthcare Group Holdings Ltd - to Sell 100% Interest in Lmi to Lantheus
Express News | Lantheus Holdings Inc - Deal Includes $350 Million Upfront and up to $400 Million in Earn-Out Payments
Express News | Lantheus Holdings Inc - Transaction Expected to Be Accretive to Adjusted EPS Within 12 Months
Press Release: Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market
Lantheus To Acquire Life Molecular Imaging For An Upfront Payment Of $350 Million To Accelerate Innovation For Patients In The Growing Alzheimer's Disease Radiodiagnostic Market >LNTH
Express News | Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market
Lantheus Increases to 12.16% Shareholding in Radiopharm With US$5m (A$8m) Placement